PALISADE BIO, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PALISADE BIO, INC. (PALI) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.82 million as of 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-20
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.82M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.22M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.47M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.96M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $1.82M 10-K · filed 2026-03-20 | |
| 2024-12-31 | $1.22M 10-K · filed 2026-03-20 | |
| 2023-12-31 | $1.47M 10-K · filed 2025-03-24 | |
| 2022-12-31 | $1.96M 10-K · filed 2024-03-26 | |
| 2021-12-31 | $1.74M 10-K · filed 2023-03-22 | |
| 2020-12-31 | $1.44M 10-K · filed 2022-03-17 | $2.32M 10-K · filed 2021-03-22 |
| 2019-12-31 | $2.61M 10-K · filed 2021-03-22 | |
| 2018-12-31 | $2.64M 10-K · filed 2020-03-27 | |
| 2017-12-31 | $6.76M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $10.12M 10-K · filed 2018-04-02 | |
| 2015-12-31 | $10.66M 10-K · filed 2017-03-23 | |
| 2014-12-31 | $11.18M 10-K · filed 2016-03-14 | |
| 2013-12-31 | $9.92M 10-K · filed 2015-03-16 | |
| 2012-12-31 | $9.17M 10-K · filed 2014-03-10 | |
| 2011-12-31 | $8.53M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |